Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
- PMID: 23787031
- PMCID: PMC3691834
- DOI: 10.1186/1750-1172-8-90
Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
Abstract
Background: Pompe disease is an autosomal recessive metabolic neuromuscular disorder caused by a deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). It has long been believed that the underlying pathology leading to tissue damage is caused by the enlargement and rupture of glycogen-filled lysosomes. Recent studies have also implicated autophagy, an intracellular lysosome-dependent degradation system, in the disease pathogenesis. In this study, we characterize the long-term impact of enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA) on lysosomal glycogen accumulation and autophagy in some of the oldest survivors with classic infantile Pompe disease (IPD).
Methods: Muscle biopsies from 8 [4 female, 4 male; 6 cross-reactive immunologic material (CRIM)-positive, 2 CRIM-negative] patients with a confirmed diagnosis of classic IPD were examined using standard histopathological approaches. In addition, muscle biopsies were evaluated by immunostaining for lysosomal marker (lysosomal-associated membrane protein-2; LAMP2), autophagosomal marker (microtubule-associated protein 1 light chain 3; LC3), and acid and alkaline ATPases. All patients received rhGAA by infusion at cumulative biweekly doses of 20-40 mg/kg.
Results: Median age at diagnosis of classic IPD was 3.4 months (range: 0 to 6.5 months; n = 8). At the time of muscle biopsy, the patients' ages ranged from 1 to 103 months and ERT duration ranged from 0 (i.e., baseline, pre-ERT) to 96 months. The response to therapy varied considerably among the patients: some patients demonstrated motor gains while others experienced deterioration of motor function, either with or without a period of initial clinical benefit. Skeletal muscle pathology included fiber destruction, lysosomal vacuolation, and autophagic abnormalities (i.e., buildup), particularly in fibers with minimal lysosomal enlargement. Overall, the pathology reflected clinical status.
Conclusions: This is the first study to investigate the impact of rhGAA ERT on lysosomal glycogen accumulation and autophagic buildup in patients with classic IPD beyond 18 months of treatment. Our findings indicate that ERT does not fully halt or reverse the underlying skeletal muscle pathology in IPD. The best outcomes were observed in the two patients who began therapy early, namely at 0.5 and 1.1 months of age.
Figures
Similar articles
-
Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.Biomolecules. 2020 Sep 18;10(9):1339. doi: 10.3390/biom10091339. Biomolecules. 2020. PMID: 32962155 Free PMC article. Review.
-
Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).Neuropathol Appl Neurobiol. 2018 Aug;44(5):449-462. doi: 10.1111/nan.12414. Epub 2017 Jul 4. Neuropathol Appl Neurobiol. 2018. PMID: 28574618
-
Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease.J Mol Med (Berl). 2017 May;95(5):513-521. doi: 10.1007/s00109-017-1505-9. Epub 2017 Feb 2. J Mol Med (Berl). 2017. PMID: 28154884
-
Autophagy in skeletal muscle: implications for Pompe disease.Int J Clin Pharmacol Ther. 2009;47 Suppl 1(Suppl 1):S42-7. doi: 10.5414/cpp47042. Int J Clin Pharmacol Ther. 2009. PMID: 20040311 Free PMC article. Review.
-
Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.Pediatrics. 2004 May;113(5):e448-57. doi: 10.1542/peds.113.5.e448. Pediatrics. 2004. PMID: 15121988
Cited by
-
Failure of Autophagy in Pompe Disease.Biomolecules. 2024 May 13;14(5):573. doi: 10.3390/biom14050573. Biomolecules. 2024. PMID: 38785980 Free PMC article. Review.
-
Blepharoptosis in infantile onset Pompe disease: Histological findings and surgical outcomes.Mol Genet Metab Rep. 2023 Mar 17;35:100969. doi: 10.1016/j.ymgmr.2023.100969. eCollection 2023 Jun. Mol Genet Metab Rep. 2023. PMID: 36967722 Free PMC article.
-
In Utero Enzyme-Replacement Therapy for Infantile-Onset Pompe's Disease.N Engl J Med. 2022 Dec 8;387(23):2150-2158. doi: 10.1056/NEJMoa2200587. Epub 2022 Nov 9. N Engl J Med. 2022. PMID: 36351280 Free PMC article.
-
IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy.Mol Ther Methods Clin Dev. 2022 Sep 24;27:109-130. doi: 10.1016/j.omtm.2022.09.010. eCollection 2022 Dec 8. Mol Ther Methods Clin Dev. 2022. PMID: 36284764 Free PMC article.
-
To detect potential pathways and target genes in infantile Pompe patients using computational analysis.Bioimpacts. 2022;12(2):89-105. doi: 10.34172/bi.2022.23467. Epub 2022 Jan 22. Bioimpacts. 2022. PMID: 35411297 Free PMC article.
References
-
- Hirschhorn R, Reuser AJJ. In: The Metabolic and Molecular Bases of Inherited Disease. 8. Scriver CR, Beaudet AL, Sly WS, Valle MD, editor. New York: McGraw-Hill; 2001. Glycogen storage disease type II: acid alpha- glucosidase (acid maltase) deficiency; pp. 3389–3420.
-
- Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR, Arnold GL, Pivnick EK, Ottinger CJ, Robinson PH. et al.Clinical outcomes after long- term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med. 2009;11:210–219. doi: 10.1097/GIM.0b013e31819d0996. - DOI - PubMed
-
- Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, Bauer MS. et al.Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res. 2009;66:329–335. doi: 10.1203/PDR.0b013e3181b24e94. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous